If you are searching for an Anduril Industries IPO date, the honest answer is short: there is not one. Palmer Luckey’s defense-tech company is still private, and neither the company nor its founder has announced a date, a timeline, or even a firm commitment to go public. Matt Milner’s “The Next Elon Musk” presentation is built partly around that gap, because it is the gap that makes pre-IPO exposure valuable. Here is what we actually know, and what an eventual IPO would even look like. We walk through the specifics in our Who Owns Anduril Industries? The Cap Table, Mapped piece. For the full backstory, see our Anduril Industries Phone Number: Why Investors Call article.
The Current State: No Announced Date
Anduril has raised money in private funding rounds rather than through public markets, and as of this writing there is no filed S-1, no roadshow, and no ticker reserved for an Anduril common stock. Luckey has spoken publicly about wanting to keep the company independent and has at times been ambivalent about a public listing, though those comments are not the same thing as a commitment either way. The reliable conclusion is that an IPO is not imminent, and any specific date you see floated online is speculation dressed up as fact.
Why the Pre-IPO Window Matters
The reason this question keeps coming up is structural. Historically, much of the biggest return in a technology company’s life cycle accrues before it goes public, when shares are still held by founders and early private investors. Once a company lists, retail investors are buying from those earlier holders, often at a meaningfully higher price. Milner’s pitch leans on exactly this logic, arguing that the ideal time to gain exposure is before an IPO happens, not after.
What an Anduril IPO Would Look Like
If Anduril does eventually go public, it would likely file a confidential draft registration with the Securities and Exchange Commission first, followed by a public S-1, a roadshow, and a pricing of shares on a major exchange. Only at that point would a public ticker exist. For now, Anduril’s valuation is a private-market number rather than a public one, reported in the tens of billions across recent funding rounds, and it will stay that way until the company decides otherwise.
The Only Current Public Backdoor
Until then, the only purchasable way to get indirect exposure in a regular brokerage account is the free ticker Milner hands out in the presentation: XOVR, the ERShares Private-Public Crossover ETF. XOVR holds Anduril alongside roughly 30 other private companies such as SpaceX, which is why Milner describes it as a pre-IPO backdoor. He is also upfront about its limits: Anduril is not in the fund’s top 10 holdings, and private companies make up only about 15% of the fund. It is exposure, but it is exposure through a diversified lens, not a direct stake.
For the full picture on the pitch and its claims, read our complete Next Elon teardown. If the pre-IPO theme is what draws you in, see our OXF AI IPO review on Alexander Green’s Anthropic backdoor pitch, and for the broader defense-tech trade, see our AI defense stocks piece.
Why the Timing Keeps Shifting
The reason no one can pin down an Anduril IPO is that the decision sits entirely with the company and its founder. Private companies go public when they want to raise capital, when their investors want liquidity, or when market conditions reward a listing, and Anduril has so far had enough private funding to avoid forcing the question. Luckey has spoken about the benefits of staying private, including the freedom to make long-term bets without quarterly pressure, and those comments suggest a founder in no particular hurry. For an investor, that cuts both ways. It means the pre-IPO window, and the scarcity that makes it valuable, could stay open for a while, or it could close quickly if conditions change. That uncertainty is exactly what the presentation monetizes, and it is the main reason the timing question has no clean answer.
Our Take
The absence of an IPO date is not a flaw in Anduril; it is simply the current reality of a company that is still growing privately. The risk to watch is the assumption that an IPO is inevitable or that it will produce a windfall for whoever bought exposure early. Those are two separate questions, and the presentation’s own language, heavy on “I believe” and “could,” reflects that uncertainty. If you want pre-IPO-style exposure today, XOVR is the mechanism Milner points to, and it is real. Whether that sliver of a private sleeve is enough for your goals is a question only you can answer.
Ready to see the research? Click here to access Matt Milner’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.